- Home
- CADL
as 06-20-2025 3:32pm EST
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 234.8M | IPO Year: | 2021 |
| Target Price: | $21.00 | AVG Volume (30 days): | 882.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.79 - $14.60 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Candel Therapeutics Inc. News
CADL Breaking Stock News: Dive into CADL Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Zacks
19 days ago
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
Insider Monkey
22 days ago
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer
Zacks
23 days ago
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
MT Newswires
24 days ago
Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug
GlobeNewswire
24 days ago
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
GlobeNewswire
25 days ago
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
Insider Monkey
a month ago
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025
Compare CADL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CADL Candel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.